The U.S. mutual fund industry is poised to see significant developments in the ongoing wave of Section 36(b) “excessive fee” litigation. Days apart in August, the Seventh Circuit Court of Appeals affirmed the grant of summary...more
10/7/2015
/ Appeals ,
Arms Length Transactions ,
Board Deferance ,
Board of Directors ,
Excessive Fees ,
Fiduciary Duty ,
Financial Adviser ,
Gartenberg Factors ,
Investment Adviser ,
Investment Company Act of 1940 ,
Mutual Funds ,
Private Right of Action ,
SCOTUS ,
Section 36(b) ,
Shareholders ,
Summary Judgment
Publicly Traded Life Sciences Companies in the United States Are an Increasingly Popular Target of Securities Fraud Class Action Lawsuits -
The past year was particularly noteworthy with respect to the relative number...more
3/19/2015
/ Biotechnology ,
Class Action ,
Compliance ,
Disclosure Requirements ,
Insider Trading ,
Life Sciences ,
Medical Devices ,
Misrepresentation ,
Pharmaceutical Industry ,
Popular ,
Publicly-Traded Companies ,
Rule 10b-5 ,
Securities Fraud ,
Surveys
Five years removed from the credit crisis and “great recession” of 2008, the U.S. fund industry still faces substantial litigation risk, both in terms of ongoing cases that challenge the core of the advisory/sub-advisory...more
Publicly Traded Life Sciences Companies in the United States Remain an Increasingly Popular Target of Securities Fraud Class Action Lawsuits:
The past year was particularly noteworthy with respect to the absolute and...more